Data supplements
Online appendices
- Appendix 1: Study design and counts of individual agents included in each group
- Appendix 10: Sensitivity analysis for meta-analytic estimates-excluding one data source at a time
- Appendix 2: ICD-9 codes used to identify the composite outcome of venous thromboembolism
- Appendix 3: Probabilistic sensitivity analysis for evaluating the impact of outcome misclassification
- Appendix 4: Sensitivity analysis for unmeasured confounding
- Appendix 5: Baseline characteristics of inflammatory bowel disease patients initiating TNF-α inhibitors or non-biologic agents
- Appendix 6: Propensity score distribution of treated and referent groups before and after weighting, Medicaid cohort
- Appendix 7: Propensity score distribution of treated and referent groups before and after weighting, Medicare cohort
- Appendix 8: Propensity score distribution of treated and referent groups before and after weighting, Optum Clinformatics cohort
- Appendix 9: Comparative risk of incident venous thromboembolism among inflammatory bowel disease patients initiating TNF-α inhibitors versus non-biologic agents in early and late follow-up periods